MNG563
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- OXIDATIVE_PHOSPHORYLATION+0.494
- MYC_TARGETS_V1+0.284
- DNA_REPAIR+0.269
- E2F_TARGETS+0.268
- NOTCH_SIGNALING+0.256
- ADIPOGENESIS+0.236
- G2M_CHECKPOINT+0.205
- MYC_TARGETS_V2+0.194
- SPERMATOGENESIS+0.143
- PEROXISOME+0.085
Top 10 suppressed
- IL6_JAK_STAT3_SIGNALING-0.554
- TNFA_SIGNALING_VIA_NFKB-0.477
- HEDGEHOG_SIGNALING-0.471
- INTERFERON_GAMMA_RESPONSE-0.450
- INFLAMMATORY_RESPONSE-0.440
- INTERFERON_ALPHA_RESPONSE-0.412
- HYPOXIA-0.397
- ALLOGRAFT_REJECTION-0.383
- TGF_BETA_SIGNALING-0.380
- IL2_STAT5_SIGNALING-0.359
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-CV-6948-01A-11R-1915-07 | — | — | 0.902 |
| 2 | 23b70cde-f829-473b-b253-fd87eef7605f | — | — | 0.891 |
| 3 | TCGA-P3-A6T6-01A-11R-A34R-07 | — | — | 0.886 |
| 4 | 3531a950-9532-4b22-93bc-f7f9551bc08c | — | — | 0.883 |
| 5 | BS_NKEAAFMW | medulloblastoma | — | 0.883 |
| 6 | TCGA-CR-6472-01A-11R-1873-07 | — | — | 0.880 |
| 7 | SAMN03290891 | — | — | 0.879 |
| 8 | TCGA-HD-A634-01A-11R-A28V-07 | — | — | 0.874 |
| 9 | MNG87 | — | — | 0.873 |
| 10 | SRR5088851 | — | — | 0.870 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 12 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| OXIDATIVE_PHOSPHORYLATION | 0.494 | Remibrutinib | — uncovered |
| MYC_TARGETS_V1 | 0.284 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.269 | Idelalisib | — uncovered |
| E2F_TARGETS | 0.268 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.256 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.236 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.205 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.194 | Idelalisib | — uncovered |
| SPERMATOGENESIS | 0.143 | Inavolisib | — uncovered |
| PEROXISOME | 0.085 | Idelalisib | — uncovered |
| APICAL_SURFACE | 0.060 | Temsirolimus | — uncovered |
| FATTY_ACID_METABOLISM | 0.022 | Inavolisib | — uncovered |